140 Million Americans Have This Genetic Problem

obesity treatment, GLP-1 drugs, semaglutide, tirzepatide, childhood obesity, and metabolic disease are transforming healthcare. In this video, we explain what’s really happening behind the science.

We are in the middle of a massive shift in how obesity is understood and treated.

But most people are only seeing the headlines.

In this conversation with @gameofpharma4233 , I break down what obesity actually is, why it’s a genetically and epigenetically driven disease, and how new medications like GLP-1 agonists are changing the way we approach treatment.

We explore what these drugs actually do, why their impact goes far beyond weight loss, and what it means when a medication starts showing benefits across conditions like Alzheimer’s, addiction, and more.

This is not just about weight.

This is about understanding one of the most complex diseases we face today and where treatment is heading next.